The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ARCUTIS BIOTHERAPEUTICS INC | COM | 03969K108 | 33,175,720 | 1,265,283 | SH | DFND | 1 | 0 | 1,265,283 | 0 | |
| AVALO THERAPEUTICS INC | COM NEW | 05338F306 | 8,020,930 | 434,033 | SH | DFND | 1 | 0 | 434,033 | 0 | |
| AVALYN PHARMACEUTICALS INC | COM SHS | 05348Y105 | 31,826,793 | 966,792 | SH | DFND | 1 | 0 | 966,792 | 0 | |
| BIOAGE LABS INC | COM | 09077V100 | 16,014,197 | 653,374 | SH | DFND | 1 | 0 | 653,374 | 0 | |
| EVOMMUNE INC | COM SHS | 30054Y107 | 25,609,072 | 1,926,943 | SH | DFND | 1 | 0 | 1,926,943 | 0 | |
| IMMUNOME INC | COM | 45257U108 | 15,521,929 | 732,512 | SH | DFND | 1 | 0 | 732,512 | 0 | |
| MAPLIGHT THERAPEUTICS INC | COM | 56565P103 | 21,914,225 | 611,446 | SH | DFND | 1 | 0 | 611,446 | 0 | |
| OCULIS HOLDING AG | ORDINARY SHARES | H5870P102 | 20,891,688 | 1,506,250 | SH | DFND | 1 | 0 | 1,506,250 | 0 | |
| RALLYBIO CORP | COM | 75120L209 | 4,809,264 | 300,579 | SH | DFND | 1 | 0 | 300,579 | 0 | |
| RECURSION PHARMACEUTICALS IN | CL A | 75629V104 | 2,185,551 | 595,518 | SH | DFND | 1 | 0 | 595,518 | 0 | |
| TREVI THERAPEUTICS INC | COM | 89532M101 | 32,500,833 | 1,742,672 | SH | DFND | 1 | 0 | 1,742,672 | 0 | |
| VAXCYTE INC | COM | 92243G108 | 82,862,571 | 1,425,470 | SH | DFND | 1 | 0 | 1,425,470 | 0 | |
| ZENAS BIOPHARMA INC | COM | 98937L105 | 12,455,641 | 490,766 | SH | DFND | 1 | 0 | 490,766 | 0 | |